Previous 10 | Next 10 |
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financial results for the third quarter of fiscal year 2023 ended March 31, 2023, before the market open on Monday, June 12, 2023. The C...
2023-05-24 08:22:51 ET Sarepta Therapeutics ( NASDAQ: SRPT ) announced Wednesday that the FDA would require additional time to review its marketing application for SRP-9001, a gene therapy targeted at certain patients with Duchenne muscular dystrophy (DMD). The announcement co...
2023-05-22 18:28:33 ET Catalent (NYSE: CTLT) investors are clearly an optimistic bunch, as lately they've been taking not-so-bad-news very positively and trading up the stock. This dynamic was clearly in force on Monday; despite a recommendation downgrade from a leading investment b...
2023-05-22 11:36:22 ET Summary Catalent has endured a series of operational and production-based hurdles over the last 2 periods. After delaying earnings 3x, it posted numbers last week, reducing guidance and growth investments going forward. Management to double the $75ȁ...
2023-05-22 09:56:53 ET Despite an over 15% rise in the previous session, Catalent ( NYSE: CTLT ) shares traded flat on Monday after JPMorgan downgraded the contract manufacturer to Neutral, citing a lack of clarity in its near-term outlook. The downgrade comes after the Some...
2023-05-19 14:11:04 ET The major market indexes shook during Friday's midday session as GOP negotiators stormed out of a debt ceiling discussion. Tracking individual stocks, Catalent ( NYSE: CTLT ) climbed as it indicated intentions to undertake cost-cutting measures, whilst Nik...
2023-05-19 13:43:07 ET Catalent, Inc. (CTLT) Q3 2023 Business Update Transcript May 19, 2023, 08:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President & Chief Executive Officer Ricky Hopson - Senior Vice...
2023-05-19 13:25:20 ET Shares of contract drug manufacturer Catalent (NYSE: CTLT) were up more than 14% Friday afternoon after the healthcare company announced updated guidance and said it was delaying its third-quarter report for a second time. The stock is down more than 18% t...
2023-05-19 08:00:31 ET Catalent ( NYSE: CTLT ) fell ~4% pre-market Friday after the contract manufacturer announced another delay for its Q3 FY23 report and lowered its full-year outlook ahead of a conference call scheduled to provide a business update. Late last week, t...
Catalent, Inc. (“Catalent” or the “Company”) (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that, in light of the circumstances described in the Company’s Notification of Late Filing o...
News, Short Squeeze, Breakout and More Instantly...
Expansion adds more temperature-controlled storage and dedicated space for FastChain ® demand-led supply service Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced it has completed expansio...
2024-06-30 17:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-28 07:15:04 ET Barclays analyst issues EQUAL-WEIGHT recommendation for CTLT on June 28, 2024 05:28AM ET. The previous analyst recommendation was Equal-Weight. CTLT was trading at $56.41 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...